A Phase 1 Study of the Safety, Pharmacokinetics, and Biological Activity of Metronomic Dosing With Orally Administered Vinorelbine Tablets in Subjects With Non-Hematologic Malignancies For Which There Are No Currently Accepted Therapies
Inclusion Criteria:
- capable of understanding study requirements and able to provide Informed Consent
- diagnosed with a non-hematologic malignancy for which there are no currently accepted
therapies
- life expectancy at least 3 months
- agreement to use medically acceptable contraception throughout the study
- willing and able to comply with the protocol requirements
Exclusion Criteria:
- currently receiving systemic treatment for malignancy
- not yet recovered from the toxicity of prior therapies
- platelet count < 100,000 cells/mm3 within 7 days prior to study entry
- ANC < 1500 cells/mm3 within 7 days prior to study entry
- hemoglobin < 8.5 g/dL within 7 days prior to study entry
- AST and/or ALT > 2.5 X ULN within 7 days prior to study entry
- total bilirubin > 1.5 X ULN within 7 days prior to study entry
- creatinine clearance < 60 mL/min (Cockroft-Gault formula) within 7 days prior to
study entry
- receipt of any investigational therapy within 3 weeks prior to study entry
- known history of HIV, HBV, and/or HCV infection
- clinically relevant active infection or serious co-morbid medical condition at study
entry
- major surgery within 4 weeks prior to study entry
- other malignancy within 3 year prior to study entry
- pregnant or breast-feeding
- presence of a concomitant disease or condition which, in the opinion of the
Investigator, could interfere with the conduct of the study or could put the subject
at unacceptable risk